{"id":396625,"date":"2020-10-19T00:00:00","date_gmt":"2020-10-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0006-2020-biopharma-epilepsy-special-topics-new-treatments-in-epilepsy-us-2020\/"},"modified":"2026-03-31T10:44:29","modified_gmt":"2026-03-31T10:44:29","slug":"sptocg0006-2020-biopharma-epilepsy-special-topics-new-treatments-in-epilepsy-us-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0006-2020-biopharma-epilepsy-special-topics-new-treatments-in-epilepsy-us-2020\/","title":{"rendered":"Epilepsy | Special Topics | New Treatments in Epilepsy | US | 2020"},"content":{"rendered":"<p>More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to AED treatment. Opportunity in this arena has spurred the development of a range of new AEDs targeting drug-resistant epilepsy, particularly highly refractory orphan pediatric subpopulations such as Lennox-Gastaut syndrome, Dravet syndrome, and acute repetitive seizures. In the past two years, six AEDs have been FDA-approved for refractory patients, and one more is on the near-term horizon. Understanding how prescribers perceive and plan to incorporate new brands in epilepsy is critical for developers facing a complicated, highly generic, and increasingly competitive market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How do neurologists perceive the clinical profiles of recently launched and emerging brands?<\/li>\n<li>How do neurologists currently prescribe or plan to prescribe new brands? How will they be incorporated into the treatment algorithm?<\/li>\n<li>What are the top reasons why some neurologists do not prescribe or would refrain from prescribing recently launched or emerging brands?<\/li>\n<li>How will the availability of new brands impact current prescribing for the broad epilepsy population, as well as for niche epilepsy subpopulations?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>United States.<\/p>\n<p><strong>Primary research: <\/strong>Survey of 98\u00a0U.S. neurologists.<\/p>\n<p><strong>Key companies: <\/strong>Aquestive Therapeutics, GW Pharmaceuticals, Neurelis, SK Biopharmaceuticals, UCB, Zogenix.<\/p>\n<p><strong>Key drugs:<\/strong> Epidiolex (CBD), Diacomit (stiripentol), Fintepla (fenfluramine), Xcopri (cenobamate), Nayzilam (intranasal midazolam), Libervant (buccal diazepam), Valtoco (intranasal diazepam).<\/p>\n","protected":false},"template":"","class_list":["post-396625","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-epilepsy","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396625\/revisions"}],"predecessor-version":[{"id":396978,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396625\/revisions\/396978"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=396625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}